ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (ACTC) (OTCBB:ACTC), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, announced today that Dr. Robert Lanza, Vice President of Research and Scientific Development of ACTC, will present before the National Academy of Sciences (NAS) at a special meeting to explore the latest developments in embryonic stem cell science and policy.
